TY - JOUR
T1 - The emerging role of cetuximab in head and neck cancer
T2 - A 2007 perspective
AU - Panikkar, Rajiv P.
AU - Astsaturov, Igor
AU - Langer, Corey J.
PY - 2008
Y1 - 2008
N2 - The integration of targeted therapies into clinical practice constitutes the paradigm of oncology treatment in the current era. Cetuximab, a recombinant human/mouse chimeric epidermal growth factor (EGFR) monoclonal antibody is a targeted agent that has seen expanding indication in recent years. Originally approved for colorectal cancer, its role in the treatment of squamous cell carcinoma of the head and neck has augmented treatment options for patients who are refractory to or cannot tolerate platinum. This article will review the science underlying cetuximab, data supporting its use in patients with locally advanced and recurrent/metastatic disease, common toxicities of therapy, and the integration of this treatment with radiation therapy.
AB - The integration of targeted therapies into clinical practice constitutes the paradigm of oncology treatment in the current era. Cetuximab, a recombinant human/mouse chimeric epidermal growth factor (EGFR) monoclonal antibody is a targeted agent that has seen expanding indication in recent years. Originally approved for colorectal cancer, its role in the treatment of squamous cell carcinoma of the head and neck has augmented treatment options for patients who are refractory to or cannot tolerate platinum. This article will review the science underlying cetuximab, data supporting its use in patients with locally advanced and recurrent/metastatic disease, common toxicities of therapy, and the integration of this treatment with radiation therapy.
KW - Animals
KW - Antibodies, Monoclonal, Humanized
KW - Antibodies, Monoclonal/therapeutic use
KW - Antineoplastic Agents/therapeutic use
KW - Carcinoma, Squamous Cell/drug therapy
KW - Cetuximab
KW - Clinical Trials as Topic
KW - ErbB Receptors/antagonists & inhibitors
KW - Head and Neck Neoplasms/drug therapy
KW - Humans
UR - http://www.scopus.com/inward/record.url?scp=37849048749&partnerID=8YFLogxK
UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=purepublist2023&SrcAuth=WosAPI&KeyUT=WOS:000252315200014&DestLinkType=FullRecord&DestApp=WOS
U2 - 10.1080/07357900701601002
DO - 10.1080/07357900701601002
M3 - Review article
C2 - 18181051
SN - 0735-7907
VL - 26
SP - 96
EP - 103
JO - Cancer Investigation
JF - Cancer Investigation
IS - 1
ER -
